News Release

Trial stopped early: Giving immunotherapy before targeted therapy improves survival in advanced melanoma

Reports and Proceedings

Georgetown University Medical Center

WASHINGTON – More people with advanced melanoma survive for two years or more when they receive a combination of two immunotherapy drugs given before a combination of two targeted therapies, if needed, compared to people who start treatment with targeted therapies. The finding comes from a clinical trial that was stopped early because definitive results became apparent sooner than expected. It provides strong evidence for how best to treat patients with melanoma that has a specific mutation: immunotherapy is the better initial approach even for people whose tumors have a mutation that could be treated by targeted therapies.

DREAMseq, a phase III, randomized clinical trial conducted at 849 U.S. locations, was led by oncology professor Michael Atkins, MD, at the Georgetown Lombardi Comprehensive Cancer Center, on behalf of the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute. The findings were presented November 16, 2021, at the inaugural American Society of Clinical Oncology (ASCO) Virtual Plenary Series.

An estimated 106,000 new melanomas cases will be diagnosed and over 7,000 people will die of the cancer in 2021, according to the National Cancer Institute. While melanoma rates rose rapidly over the past few decades, the latest Annual Report to the Nation on the Status of Cancer noted that mortality rates are now declining, reflecting a significant increase in survival due to improved treatment options, among other factors.

“The drug combinations tested in this trial all improve survival compared to prior standards of care, but we now know which combination should be administered first to achieve maximum benefit for the vast majority of our patients,” says Atkins. “This trial should provide clearer guidance to clinicians on when to administer particular treatments.”

Starting in 2015, 265 trial participants with metastatic melanoma were randomly assigned to two groups; each group received one drug combination followed by the other combination if their cancer resisted the first combination.

Each regimen had its own distinct method of combating melanoma. One worked by targeting the effects of a mutation in the BRAF gene with the drugs dabrafenib and trametinib, which are taken in pill form. Everyone in the trial had a melanoma that contained a BRAF V600 mutation that is known to drive tumor proliferation. Working together, the two targeted drugs inhibit the function of the proteins associated with the BRAF mutation, leading to direct tumor cell killing.

The other two-drug combination utilized the immunotherapy drugs ipilimumab and nivolumab. They were given intravenously and function by disabling the cancer’s defense mechanisms, thereby unleashing the body’s antitumor immunity.

The trial outcomes were definitive enough that the trial is being stopped and reported early, with 59 percent of patients having been on the trial for two years. The two-year overall survival rate for people who first received the immunotherapies was 72 percent versus 52 percent for those who initially got the targeted therapies. Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on the immunotherapies. 

Other trial findings are intriguing but point to uncertainties that will need to be teased out in future analyses or studies. Overall response rates, which indicate who had a partial or complete response to the drugs, were similar for all permutations of drug administration except for patients who received targeted therapies first and then got immunotherapy, indicating that immunotherapy may not work well after targeted therapy.

“One conundrum in the data showed that some patients don't do well on initial immunotherapy treatments and for some reason switching to targeted therapies did not help,” says Atkins. “We are focusing on trying to determine why there was no benefit for this small group of patients.”

Given the clearer advantage for starting with immunotherapy, which is not dependent on having a BRAF mutation, the researchers believe all patients with metastatic melanoma who don’t have other complicating factors should now be treated first with immunotherapy. What this study does not resolve is what immunotherapy regimen is the best initial treatment. That question is continuing to be addressed in other clinical trials.

“While this trial focuses on melanoma, it could have significant implications for the treatment of other forms of cancer where immunotherapies are increasingly part of treatment regimens,” says Atkins.

### Identifier: NCT02224781: DREAMSeq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

In addition to Atkins, the other authors of the abstract include Sandra Lee, Dana Farber Cancer Institute, Boston; Bartosz Chmielowski and Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California Los Angeles; Ahmad A. Tarhini, H. Lee Moffitt Cancer Center and Research Institute, Tampa; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York; and John M. Kirkwood, Pittsburgh Cancer Institute.

Atkins reports that he serves or has served recently on advisory boards for Bristol-Myers Squibb, Merck & Co., Genentech, Amgen, Novartis, Pfizer, Arrowhead, Eisai, Aveo, Werewolf, Fathom, Pneuma, Leads, Pyxis Oncology, PACT, Elpis, X4Pharma, ValoHealth, ScholarRock, Surface, Takeda and Simcha. He has also been a consultant to Bristol-Myers Squibb, Merck, Novartis, Pfizer, Genentech-Roche, Exelixis, ImmunoCore, Iovance, COTA, Idera, Agenus, Apexigen, Asher Bio, Neoleukin, Adagene, AstraZeneca, Calithera, SeaGen and Sanofi.

ECOG-ACRIN received funding for this trial from the National Cancer Institute, with additional support from Bristol-Myers Squibb, the manufacturer of ipilimumab (Yervoy®) and nivolumab (Opdivo®), and from Novartis, the company that commercializes dabrafenib (Tafinlar®) and trametinib (Mekinist™).

About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center is designated by the National Cancer Institute (NCI) as a comprehensive cancer center. A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington D.C. area. It serves as the research engine for MedStar Health, Georgetown University’s clinical partner. Georgetown Lombardi is also an NCI recognized consortium with John Theurer Cancer Center/Hackensack Meridian Health in Bergen County, New Jersey. The consortium reflects an integrated cancer research enterprise with scientists and physician-researchers from both locations. Georgetown Lombardi seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic, translational and clinical research, patient care, community education and outreach to service communities throughout the Washington region, while its consortium member John Theurer Cancer Center/Hackensack Meridian Health serves communities in northern New Jersey. Georgetown Lombardi is a member of the NCI Community Oncology Research Program (UG1CA239758). Georgetown Lombardi is supported in part by a National Cancer Institute Cancer Center Support Grant (P30CA051008). Connect with Georgetown Lombardi on Facebook ( and Twitter (@LombardiCancer).



Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.